240 related articles for article (PubMed ID: 26198842)
1. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.
Trachtman H; Vento S; Herreshoff E; Radeva M; Gassman J; Stein DT; Savin VJ; Sharma M; Reiser J; Wei C; Somers M; Srivastava T; Gipson DS
BMC Nephrol; 2015 Jul; 16():111. PubMed ID: 26198842
[TBL] [Abstract][Full Text] [Related]
2. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Trachtman H; Vento S; Gipson D; Wickman L; Gassman J; Joy M; Savin V; Somers M; Pinsk M; Greene T
BMC Nephrol; 2011 Feb; 12():8. PubMed ID: 21310077
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.
Joy MS; Gipson DS; Powell L; MacHardy J; Jennette JC; Vento S; Pan C; Savin V; Eddy A; Fogo AB; Kopp JB; Cattran D; Trachtman H
Am J Kidney Dis; 2010 Jan; 55(1):50-60. PubMed ID: 19932542
[TBL] [Abstract][Full Text] [Related]
4. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
Sinha A; Bajpai J; Saini S; Bhatia D; Gupta A; Puraswani M; Dinda AK; Agarwal SK; Sopory S; Pandey RM; Hari P; Bagga A
Kidney Int; 2014 Mar; 85(3):649-58. PubMed ID: 24429405
[TBL] [Abstract][Full Text] [Related]
5. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Spino C; Kaskel FJ; Friedman A; Moxey-Mims MM; Fine RN; Gassman JJ; Kopp JB; Walsh L; Wang R; Gipson DS
Am J Kidney Dis; 2021 Feb; 77(2):216-225. PubMed ID: 32791086
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.
Joy MS; Gipson DS; Dike M; Powell L; Thompson A; Vento S; Eddy A; Fogo AB; Kopp JB; Cattran D; Trachtman H
Clin J Am Soc Nephrol; 2009 Jan; 4(1):39-47. PubMed ID: 19073787
[TBL] [Abstract][Full Text] [Related]
7. Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome.
Sgambat K; Banks M; Moudgil A
Pediatr Nephrol; 2013 Nov; 28(11):2131-5. PubMed ID: 23793883
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment.
Usta M; Ersoy A; Dilek K; Ozdemir B; Yavuz M; Güllülü M; Yurtkuran M
J Intern Med; 2003 Mar; 253(3):329-34. PubMed ID: 12603500
[TBL] [Abstract][Full Text] [Related]
9. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
Meijers B; Maas RJ; Sprangers B; Claes K; Poesen R; Bammens B; Naesens M; Deegens JK; Dietrich R; Storr M; Wetzels JF; Evenepoel P; Kuypers D
Kidney Int; 2014 Mar; 85(3):636-40. PubMed ID: 24402090
[TBL] [Abstract][Full Text] [Related]
10. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.
Peyser A; Machardy N; Tarapore F; Machardy J; Powell L; Gipson DS; Savin V; Pan C; Kump T; Vento S; Trachtman H
BMC Nephrol; 2010 Jan; 11():2. PubMed ID: 20113498
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.
Bock ME; Price HE; Gallon L; Langman CB
Clin J Am Soc Nephrol; 2013 Aug; 8(8):1304-11. PubMed ID: 23620441
[TBL] [Abstract][Full Text] [Related]
13. Aggressive treatment may be needed for idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions.
Cheng P; Xie Q; Liu S; Liu X; Wang L; Hao CM
Rev Assoc Med Bras (1992); 2024; 70(4):e20230871. PubMed ID: 38716932
[TBL] [Abstract][Full Text] [Related]
14. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN; Alpers CE; Barratt J; Bieler S; Canetta P; Chae DW; Coppock G; Diva U; Gesualdo L; Heerspink HJL; Inrig JK; Kirsztajn GM; Kohan D; Komers R; Kooienga LA; Lieberman K; Mercer A; Noronha IL; Perkovic V; Radhakrishnan J; Rote W; Rovin B; Tesar V; Trimarchi H; Tumlin J; Wong MG; Trachtman H;
N Engl J Med; 2023 Dec; 389(26):2436-2445. PubMed ID: 37921461
[TBL] [Abstract][Full Text] [Related]
15. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Nachman PH; Kretzler M; Spino C; Komers R; Tuller S; Perumal K; Massengill SF; Kamil ES; Oh G; Selewski DT; Gipson P; Gipson DS
Clin J Am Soc Nephrol; 2018 Mar; 13(3):414-421. PubMed ID: 29167190
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis.
Chiou YY; Lee YC; Chen MJ
Curr Med Res Opin; 2017 Aug; 33(8):1389-1399. PubMed ID: 28436233
[TBL] [Abstract][Full Text] [Related]
17. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
[TBL] [Abstract][Full Text] [Related]
18. Primary FSGS in Nephrotic Adults: Clinical Profile, Response to Immunosuppression and Outcome.
Bagchi S; Agarwal S; Kalaivani M; Bhowmik D; Singh G; Mahajan S; Dinda A
Nephron; 2016; 132(2):81-5. PubMed ID: 26799973
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life.
Gipson DS; Trachtman H; Kaskel FJ; Radeva MK; Gassman J; Greene TH; Moxey-Mims MM; Hogg RJ; Watkins SL; Fine RN; Middleton JP; Vehaskari VM; Hogan SL; Vento S; Flynn PA; Powell LM; McMahan JL; Siegel N; Friedman AL
Kidney Int; 2011 Mar; 79(6):678-685. PubMed ID: 21178977
[TBL] [Abstract][Full Text] [Related]
20. Interventions for focal segmental glomerulosclerosis in adults.
Hodson EM; Sinha A; Cooper TE
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD003233. PubMed ID: 35224732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]